newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

  • IGC Pharma announced the expansion of its Phase 2 CALMA clinical trial for investigational drug IGC-AD1 by opening a new site at the University of South Florida.
  • Dr. Ram Bishnoi serves as the Principal Investigator for the new University of South Florida Department of Psychiatry and Behavioral Neurosciences site.
  • Enrollment at the new site has commenced with four participants already enrolled to accelerate recruitment timelines.
  • The CALMA trial is a randomized, double-blind, placebo-controlled study evaluating IGC-AD1 for reducing agitation in patients with Alzheimer's disease.
  • IGC Pharma leverages AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting for Alzheimer's and metabolic disorders.
  • The company holds more than 30 patent filings with 12 patents granted for its pipeline including IGC-AD1, TGR-63, and early-stage neurodegeneration programs.
  • The press release includes forward-looking statements regarding risks such as regulatory approval, AI algorithm performance, and economic conditions.